All In MedTech

FDA Clearance Tracker · P970004-S340

InterStim™ Therapy System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 22, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 22, 2022

Approved

Time to decision

193 days

Received Aug 13, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P970004-S340
Device name
InterStim™ Therapy System
Applicant location
Minneapolis, MN
Received
Aug 13, 2021
Decided
Feb 22, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P970004

Device type

Device class
Class III
Regulation
21 CFR 876.5270

Every decision under product code EZW

FDA's approval statement

As written in FDA's record.

Approval for the InterStim X INS (Model 97800) and its associated software applications (Model A51300, Model A52300).

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.